Biogen Inc BIIB:NASDAQ (Common Stock)

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
429.87 0.94   0.22%1,859,1813.4M
Market data is delayed by at least 20 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Previous close 3/27/2015

Latest News Headlines for Biogen Inc

European Medicines Agency Validates Marketing Authorisation Application for ZINBRYTA(TM) (Daclizumab High-Yield Process) for Treatment of MS

CAMBRIDGE, Mass. & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--March 27, 2015-- Today Biogen (NASDAQ: BIIB) and AbbVie (NYSE: ABBV) announced that the European Medicines Agency (EMA) has validated the companies' Marketing Authorisation Application (MAA) for ZINBRYTA(TM) (daclizumab high-yield process) for the treatment of relapsing forms of multiple sclerosis (MS) in the European Union (EU). Validation confirms that the submission is complete and signifies the initiation of the review process by the EMA's Committee for Medicinal Products for Human Use (CHMP).

Biogen Idec Becomes Biogen

New Corporate Identity and Brand Reflect Company's Heritage and Commitment to Patients and Science CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 23, 2015-- Effective today, Biogen Idec is known simply as Biogen (NASDAQ: BIIB). The company has introduced a new corporate identity and logo that reflect both its evolution and focus on bringing forth new therapies in areas of high unmet need -- while honoring Biogen's scientific heritage and legacy as a pioneer in the biotechnology industry. For more information and to read a letter about today's announcement from Chief Executive Officer George A. Scangos, Ph.D., visit the company's new website at www.biogen.com.

Biogen Idec Presents Positive Interim Results -2-

(2) World Health Organization Dementia a Public Health Priority. http://www.who.int/mental_health/publications/dementia_report_2012/en/. Accessed 10 Dec 2014. CONTACT: Biogen Idec

View more recent headlines

Peers Information HelpBIIB Biogen Inc vs. Peers

BIIB
Biogen Inc
26.64%
-4.05%
Johnson & Johnson
Pfizer Inc.
10.85%
Merck & Co., Inc.
1.69%
-11.90%
AbbVie Inc
BIIB
Biogen Inc
0.00%
Johnson & Johnson
2.79%
Pfizer Inc.
3.24%
Merck & Co., Inc.
3.12%
AbbVie Inc
3.54%
BIIB
Biogen Inc
0.22%
Johnson & Johnson
0.20%
Pfizer Inc.
1.08%
Merck & Co., Inc.
0.26%
AbbVie Inc
0.66%
Compare these stocks

Latest Annual and Quarterly SEC Filings

More Filings
10-K

This report contains detailed information about the company's business finances and management.

10-Q

Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Biogen Inc., formerly Biogen Idec Inc., is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company’s products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. AVONEX is prescribed treatments for relapsing forms of multiple sclerosis (MS). AVONEX is a recombinant form of the interferon beta protein produced in the body in response to viral infection. TYSABRI is a monoclonal antibody approved in numerous countries as a monotherapy treatment for relapsing MS and to treat Crohn’s disease. The Company’s RITUXAN is a monoclonal antibody therapeutic used to treat non-Hodgkin’s lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia among others. FAMPYRA addresses the need of walking improvement in adult patients with MS who have walking disability and for the treatment of psoriasis.

https://www.biogen.com/

Loading...

collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open430.12
Previous Close428.93
Day High436.67
Day Low429.36
52 Week High3/20/2015 | 480.18
52 Week Low4/15/2014 | 272.02
% Off 52 Week High-10.48%
% Off 52 Week Low58.03%
Beta (5 Yr)1.03
Volatility Avg3/27/2015 | 35.59
10-Day Avg. Volume3,383,005
Market data is delayed by at least 20 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)12/31/2014 | 12.38
P/E Ratio12/31/2014 | 34.7
Market CapLarge Cap | 100.9B
Shares Outstanding234.61M
Float234.4M

expand, down-facing arrow indicating expanded view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield--
Ex-Date--
Dividend Announcement--
Date of Record--
Payable-- - --
Payable Date--

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short3.59M
Short Ratio2.4
Short % of Float1.53%
As of 3/15/2015